HuMoG (Human Menopausal Gonadotropin) is a hormonal substance containing FSH and LH in a ratio 1:1 in the female, HuMoG stimulates both the growth and the maturation of follicles, it induces an increase in the oestrogen levels and a proliferation of the endometrium.
Ovitrelle (INN choreo gonadotropin alfa) is a medicinal product of choriogonadotropin alfa produced by recombinant DNA techniques. It shares the amino acid sequence with urinary hCG. Chorionic gonadotropin binds on the ovarian theca (and granulosa) cells to a transmembrane receptor shared with the luteinising hormone, the LH/CG receptor. The principal pharmacodynamic activity in women is oocyte meiosis resumption, follicular rupture (ovulation), corpus luteum formation and production of progesterone and estradiol by the corpus luteum.
In women, chorionic gonadotropin acts as a surrogate luteinising hormone surge that triggers ovulation.
Luveris (INN lutropin alfa) is a sterile lyophilized powder composed of recombinant human luteinizing hormone, r-hLH. r-hLH is a heterodimeric glycoprotein consisting of two non-covalently linked subunits (designated α and β) of 92 and 121 amino acids, respectively. The carbohydrate chain attachment to the r-hLH protein core occurs via N- but not O-linkage. The N-glycosylation sites are Asn-52 and Asn-78 for the α–subunit and Asn-30 for the β–subunit. The β-chain has an N-glycosylation site and its structure and glycosylation pattern are very similar to that of pituitary-derived hLH. The production process involves expansion of genetically modified Chinese Hamster Ovary (CHO) cells from an extensively characterized cell bank into large scale cell culture processing.
GONAL-f (recombinant follitropin alfa for injection) is prescribed to supplement or replace naturally occurring FSH, an essential hormone to treat infertility in both women and men. GONAL-f® has been approved in around 100 countries worldwide for stimulating the growth of ovarian follicles and ovulation in women.
For males, GONAL-f has been approved in more than 80 countries worldwide, including Japan, for gonadal dysfunction associated with absence of sperm in the semen or male hypogonadotropic hypogonadism. In certain markets where GONAL-f is approved for this indication, the therapy needs to be in combination with human chorionic gonadotropin (hCG).
